BioLargo Subsidiary Clyra Medical Signs Exclusive Distribution Agreement with Al- Hikma FZCO for ViaCLYR(TM) Across the Middle East, North Africa, and Adjacent Markets
Rhea-AI Summary
BioLargo (OTCQX: BLGO) subsidiary Clyra Medical signed an exclusive distribution agreement with Al-Hikma FZCO to commercialize ViaCLYR™ across the Gulf Cooperation Council, the Levant, North Africa, and adjacent markets. The deal includes territory exclusivity tied to performance and cooperative country-level regulatory work is underway.
ViaCLYR™ uses Clyra's Clyrasept™ Copper-Iodine Complex Solution (CICS) as a broad-spectrum antimicrobial for wound irrigation. The partners plan coordinated regulatory filings and commercial rollout across a region serving over 500 million people.
Positive
- Exclusive distribution across GCC, Levant, North Africa, adjacent markets
- Regulatory work for country-level approvals has already begun
- Access to >500 million population across the covered territory
- Partner fit: Al-Hikma has established wound-management portfolio and regional networks
Negative
- Commercial sales dependent on country-level regulatory approvals
- Territory exclusivity is performance-contingent, posing execution risk
News Market Reaction – BLGO
In the May 5 session, BLGO declined 0.83%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Agreement Extends Clyra's International Reach Through One of the Region's Premier Healthcare Distributors
WESTMINSTER, CA / ACCESS Newswire / May 5, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator, today announced that its subsidiary Clyra Medical Technologies, Inc. has entered into an exclusive distribution agreement with Al- Hikma FZCO, headquartered in Dubai, United Arab Emirates, to commercialize ViaCLYR™ across a broad territory spanning the Gulf Cooperation Council, the Levant, North Africa, and select adjacent markets.
The agreement reflects standard international distribution terms, including territory exclusivity tied to performance and the cooperation and protections customary in such contracts. Country-level regulatory work required for commercial sales across the territory has begun in key areas through a cooperative process between the parties.
ViaCLYR™ is Clyra's advanced wound irrigation solution, powered by its proprietary Clyrasept™ Copper-Iodine Complex Solution (CICS) technology - a broad-spectrum antimicrobial designed to be effective, biocompatible, and supportive of the body's natural healing processes. https://www.clyramedical.com/clyraproducts
"Al- Hikma FZCO is exactly the kind of partner we wanted in this region - established, deeply networked across the Middle East and North Africa, and credible with regulators and the clinical community," said Steve Harrison, Chief Executive Officer of Clyra Medical Technologies. "Their portfolio strength in wound management makes ViaCLYR™ a natural fit, and with regulatory work already in motion we are well positioned to build commercial momentum."
Dennis P. Calvert, Chairman of Clyra Medical Technologies and CEO of BioLargo, Inc., added, "This agreement meaningfully expands Clyra's international footprint and reflects our strategy of partnering with proven, well-established distributors. Al- Hikma FZCO serves a population of more than 500 million people across some of the most dynamic healthcare markets in the world."
"Clyra's copper-iodine technology is differentiated and aligned with our mission to bring innovative, high-quality healthcare products to the communities we serve," said Dr. Ali Farooq Abdul-Qader, Founder and Group CEO of Al- Hikma FZCO. "We look forward to a long and productive partnership."
About Al- Hikma FZCO
Al- Hikma FZCO is a specialized healthcare distribution and marketing group headquartered in Dubai, UAE. Founded in 2005 by Dr. Ali Farooq Abdul-Qader, the company exports to approximately 25 countries, maintains more than 50 local distributor partnerships, employs around 500 people, and serves a population of more than 500 million across the Middle East, North Africa, and adjacent regions. Portfolio focus areas include conventional pharmaceuticals, wound management, medical devices, generics, food supplements, and OTC products. See www.alhikmaco.com.
About Clyra Medical Technologies
Clyra Medical Technologies, Inc., a subsidiary of BioLargo, Inc., focuses on infection control and advanced wound care. Founded in 2012, the company develops and commercializes wound care solutions based on its proprietary Copper-Iodine Complex Technology, with FDA-cleared products delivered through strategic distribution partnerships. See www.ClyraMedical.com.
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, advanced water and wastewater treatment, odor and VOC control, air quality, energy efficiency and safe on-site energy storage, and infection control. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships. See www.BioLargo.com.
Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about BioLargo's (the "Company's") expectations regarding anticipated revenue and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied. Risks include, without limitation: regional economic conditions; competition and rapid technological change; the Company's ability to manage product introductions and stimulate demand on a timely basis; and the Company's dependency on the performance of its distributors. More information is included in the Company's SEC filings, including the "Risk Factors" and "Management's Discussion and Analysis" sections of its most recent Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire